Mylan, Inc. (MYL)
-NasdaqGS 31.40 
0.70(2.28%) 18 May 04:00 SGT|After Hours
:
31.42 0.02 (0.07%) 18 May 04:42 SGT
| Prev Close: | 30.70 |
|---|
| Open: | 30.90 |
|---|
| Bid: | 31.03 x 300 |
|---|
| Ask: | 31.79 x 300 |
|---|
| 1y Target Est: | 32.03 |
|---|
| Beta: | 1.21 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 30.84 - 31.47 |
|---|
| 52wk Range: | 20.50 - 31.47 |
|---|
| Volume: | 5,720,298 |
|---|
| Avg Vol (3m): | 6,186,660 |
|---|
| Market Cap: | 11.97B |
|---|
| P/E (ttm): | 20.98 |
|---|
| EPS (ttm): | 1.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Drugmaker Actavis' shares upAP(Thu, 16 May)
- Ahead of the Bell: Drugmaker Actavis' shares upAP(Thu, 16 May)
- Ahead of the Bell: Mylan 1Q profit sinks 17 pctAP(Fri, 3 May)
- Teva Pharmaceutical 1Q profit sinks 27 percentAP(Fri, 3 May)
- Valeant Pharma takes 1Q loss on Medicis costsAP(Thu, 2 May)
- Strides Arcolab unit, Pfenex in biosimilars JVReuters(Wed, 17 Apr)
- Strides Arcolab shares sink on dividend worriesReuters(Thu, 28 Feb)
- Mylan to buy injectable drugs unit of Strides for $1.6 billionReuters(Thu, 28 Feb)
- Mylan to buy injectable drugs unit of Strides for $1.6 billionReuters(Thu, 28 Feb)
- Mylan, Biocon help market generic insulin drugsAP(Thu, 14 Feb)
Key Statistics
| Forward P/E (1 yr): | 9.72 |
|---|
| P/S (ttm): | 1.71 |
|---|
| Ex-Dividend Date: | 27-Jun-07 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.86 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.67 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.22 |
|---|
Business Summary
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide.
View More